Company intelligence / Profile preview

NEOBio

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

NeoBio is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative small molecule and biologic therapies for oncology. The company's primary focus is on targeting key oncogenic drivers and signaling pathways, such as KRAS and SHP2, to address unmet needs in solid tumors. NeoBio's lead programs include inhibitors designed to treat KRAS G12C-mutant non-small cell lung cancer and colorectal cancer. By leveraging its internal R&D capabilities, the company aims to develop both monotherapies and combination treatments to overcome drug resistance in cancer patients.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on NEOBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEOBio.

Explore the full profile